Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Serum soluble urokinase plasminogen activator receptor (suPAR) in adults with growth hormone deficiency

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Genotype-phenotype associations in PPGLs in 59 patients with variants in SDHX genes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Levels of endocrine-disrupting chemicals are associated with changes in the peri-pubertal epigenome

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Sacubitril/valsartan increases postprandial gastrin and cholecystokinin in plasma

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Role of fasting duration and weekday in incretin and glucose regulation

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Secretion of parathyroid hormone may be coupled to insulin secretion in humans

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Association Between Elevated suPAR, a New Biomarker of Inflammation, and Accelerated Aging

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Validation of suPAR turbidimetric assay on Cobas® (c502 and c702) and comparison to suPAR ELISA

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Elevated suPAR Is an Independent Risk Marker for Incident Kidney Disease in Acute Medical Patients

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Growth hormone deficiency (GHD) syndrome is associated with adverse levels of several risk factors for cardiovascular diseases (CVD), including metabolic inflammation. However, the impact of GHD and GH treatment on low-grade inflammation is unknown. The aim of the study was to establish the level of the low-grade inflammation biomarker soluble urokinase plasminogen activator receptor (suPAR) in adults with GHD and the response to long-term GH treatment. Measurements of suPAR and CRP were performed in bio-bank serum samples from 72 adults, 34 males and 38 females, with GHD before and during at least 5 years of GH treatment. Mean age was 52.5 ± 15.5 years, BMI 27.3 ± 5 kg/m2. Clinical evaluations and blood sampling were performed at routine visits. Data on demography, anthropometry, lab results and clinical events were retrieved from post-marketing surveillance study databases and medical records. suPAR and high-sensitive (hs) CRP were analysed using ELISA and immunochemistry, respectively. At baseline blood pressure, lipid profile and fasting glucose were within the normal reference range. Baseline geometric mean and 95% CI of suPAR was 2.9 (2.7-3.3) ng/mL and of CRP 2.3 (0.6-4.0) mg/L. Mean follow-up was 8 ± 2 years. The suPAR levels remained stable during follow-up, although individual increases were seen on occurrence or presence of co-morbidities. In contrast, levels of CRP decreased. In conclusion, the decrease in CRP and indirectly the absence of an expected increase in suPAR over time indicates a favourable effect of GH on low-grade inflammation.

Original languageEnglish
JournalEndocrine Connections
Volume8
Issue number6
Pages (from-to)772-779
Number of pages8
ISSN2049-3614
DOIs
Publication statusPublished - 1 Jun 2019

    Research areas

  • Growth hormone deficiency in adults, Growth hormone treatment, Low-grade inflammation, SuPAR

ID: 57307125